Treatment options for POEMS syndrome

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman's disease, thrombocytosis, papilledema, peripheral oedema, pleural effusions, ascites, fingernail clubbing and white nails, is the first step in effectively managing the disease. More than 95% of patients will have monoclonal lambda sclerotic plasmacytoma(s) or bone marrow infiltration. In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion. Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion, and for those who have not demonstrated stabilisation of their disease 3 - 6 months after completing radiation therapy. For those patients with diffuse disease, systemic therapy is indicated. Useful approaches include therapy with corticosteroids, low dose alkylator therapy and high dose chemotherapy with peripheral blood stem cell transplant. Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.

Original languageEnglish (US)
Pages (from-to)945-953
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

POEMS Syndrome
Plasmacytoma
Nails
Therapeutics
Giant Lymph Node Hyperplasia
Paraneoplastic Syndromes
Bone and Bones
Thrombocytosis
Papilledema
Paraproteinemias
Alkylating Agents
Peripheral Nervous System Diseases
Pleural Effusion
Ascites
Edema
Adrenal Cortex Hormones
Radiotherapy
Bone Marrow
Radiation
Transplants

Keywords

  • Castleman's disease
  • Monoclonal gammopathy of undetermined significance
  • Multiple myeloma
  • Paraneoplastic syndrome
  • POEMS syndrome
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Treatment options for POEMS syndrome. / Dispenzieri, Angela; Gertz, Morie.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 6, 06.2005, p. 945-953.

Research output: Contribution to journalArticle

@article{669988d8e98b442292a621052986a71e,
title = "Treatment options for POEMS syndrome",
abstract = "POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman's disease, thrombocytosis, papilledema, peripheral oedema, pleural effusions, ascites, fingernail clubbing and white nails, is the first step in effectively managing the disease. More than 95{\%} of patients will have monoclonal lambda sclerotic plasmacytoma(s) or bone marrow infiltration. In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion. Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion, and for those who have not demonstrated stabilisation of their disease 3 - 6 months after completing radiation therapy. For those patients with diffuse disease, systemic therapy is indicated. Useful approaches include therapy with corticosteroids, low dose alkylator therapy and high dose chemotherapy with peripheral blood stem cell transplant. Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.",
keywords = "Castleman's disease, Monoclonal gammopathy of undetermined significance, Multiple myeloma, Paraneoplastic syndrome, POEMS syndrome, Vascular endothelial growth factor",
author = "Angela Dispenzieri and Morie Gertz",
year = "2005",
month = "6",
doi = "10.1517/14656566.6.6.945",
language = "English (US)",
volume = "6",
pages = "945--953",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Treatment options for POEMS syndrome

AU - Dispenzieri, Angela

AU - Gertz, Morie

PY - 2005/6

Y1 - 2005/6

N2 - POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman's disease, thrombocytosis, papilledema, peripheral oedema, pleural effusions, ascites, fingernail clubbing and white nails, is the first step in effectively managing the disease. More than 95% of patients will have monoclonal lambda sclerotic plasmacytoma(s) or bone marrow infiltration. In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion. Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion, and for those who have not demonstrated stabilisation of their disease 3 - 6 months after completing radiation therapy. For those patients with diffuse disease, systemic therapy is indicated. Useful approaches include therapy with corticosteroids, low dose alkylator therapy and high dose chemotherapy with peripheral blood stem cell transplant. Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.

AB - POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman's disease, thrombocytosis, papilledema, peripheral oedema, pleural effusions, ascites, fingernail clubbing and white nails, is the first step in effectively managing the disease. More than 95% of patients will have monoclonal lambda sclerotic plasmacytoma(s) or bone marrow infiltration. In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion. Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion, and for those who have not demonstrated stabilisation of their disease 3 - 6 months after completing radiation therapy. For those patients with diffuse disease, systemic therapy is indicated. Useful approaches include therapy with corticosteroids, low dose alkylator therapy and high dose chemotherapy with peripheral blood stem cell transplant. Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.

KW - Castleman's disease

KW - Monoclonal gammopathy of undetermined significance

KW - Multiple myeloma

KW - Paraneoplastic syndrome

KW - POEMS syndrome

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=21744438606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744438606&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.6.945

DO - 10.1517/14656566.6.6.945

M3 - Article

VL - 6

SP - 945

EP - 953

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -